Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is invalid and is
Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIAConfirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C.,.
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from.
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing.
Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placementAdditional advance of $25.0 million from HealthCare Royalty under current financing agreement